Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Aug 19, 2023 8:58am
RE:RE:RE:61 Cents
Amen - Pronorvista !!!
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Aug 19, 2023 8:56am
RE:RE:RE:RE:61 Cents
Not just a discount period Harper. With the volumes so low (no interest or excitement), there was no market here. Without a market, you can't establish a reasonable price for your shares
...more
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Aug 17, 2023 1:53pm
RE:RE:RE:61 Cents
Some would say this has been the discount period since science provided a path forward from the elevated enzyme issue.
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Comment by
Pronorvista
on Aug 17, 2023 1:35pm
RE:RE:61 Cents
When the volume will start it will not be easy to take a position at a discount
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Comment by
Pronorvista
on Aug 17, 2023 12:50pm
RE:RE:61 Cents
Only 18,000 shares to sell between 0.57 and 0.70 really not easy to take a big position, only believers who are waiting for the big news not selling at such low prices
(7)
•••
SuperSlug
X
View Profile
View Bullboard History
Comment by
SuperSlug
on Aug 17, 2023 12:43pm
RE:61 Cents
Very very low volumes, doesn't mean much.
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Aug 17, 2023 10:17am
ATE
Depth by Price for T : ATE at 2023-08-17 10:00:06 Bid Ask Price Volume Orders 0.53 7,000 2 0.54 5,000 1
...more
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Aug 17, 2023 9:38am
ATE
Maybe Legault and his group will have enough contact to pick up the 2000 shares at 0.58
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Aug 16, 2023 7:35pm
RE:RE:Big Money
Agreed - it is.
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Aug 16, 2023 12:23pm
RE:Big Money
IMO the Phase 2 readout Q2 2024 is THE critical milestone.
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Aug 16, 2023 11:57am
Big Money
for drug companies (and there shareholders) if they are succesful. novo nordisk has now become the 2nd most valuable company in europe with it's diabetes and weight loss drugs ozempic and wegovy
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Aug 14, 2023 10:11am
No new delays
same timeline for all upcoming milestones. so i think if we get possitive PK/PD study results in the next quarterly report (sep-nov)or the following month (oct-dec calendar Q4) , and the
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 14, 2023 7:03am
New Press Release - Antibe Reports Q1 2024 Interim Financial and Operating Results
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study- PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024- Ended quarter with $34.3 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage...
read article.
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Aug 11, 2023 10:11am
61 Cents
up 22% so far. more friends and family of insiders buying? lol we will find out next week if we have something in the bag
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Aug 11, 2023 9:06am
good news
the market is red, ate will be moving higher
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >